Order Article Reprints

Bonnet C, Dupuis J, Tilly H, Lamy T, Fruchart C, le Gouill S, Thieblemont C, Morschhauser F, Casasnovas O, Bouabdallah K, et al. Ibrutinib Associated with Rituximab-Platinum Salt-Based Immunochemotherapy in B-Cell Lymphomas: Results of a Phase 1b-II Study of the LYSA Group. Cancers. 2022; 14(7):1761. https://doi.org/10.3390/cancers14071761

Bonnet, Christophe, Jehan Dupuis, Hervé Tilly, Thierry Lamy, Christophe Fruchart, Steven le Gouill, Catherine Thieblemont, Franck Morschhauser, Olivier Casasnovas, Krimo Bouabdallah, and et al. 2022. "Ibrutinib Associated with Rituximab-Platinum Salt-Based Immunochemotherapy in B-Cell Lymphomas: Results of a Phase 1b-II Study of the LYSA Group" Cancers 14, no. 7: 1761. https://doi.org/10.3390/cancers14071761

Bonnet, C., Dupuis, J., Tilly, H., Lamy, T., Fruchart, C., le Gouill, S., Thieblemont, C., Morschhauser, F., Casasnovas, O., Bouabdallah, K., Ghesquieres, H., Van Den Neste, E., André, M., Cartron, G., & Salles, G. (2022). Ibrutinib Associated with Rituximab-Platinum Salt-Based Immunochemotherapy in B-Cell Lymphomas: Results of a Phase 1b-II Study of the LYSA Group. Cancers, 14(7), 1761. https://doi.org/10.3390/cancers14071761